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COVID-19 Infection Unmasking Brugada Syndrome
David Chang, MD, Moussa Saleh, MD, Youssef Garcia-Bengo, MD, Evan Choi, MD,
Laurence Epstein, MD, Jonathan Willner, MD
From the Department of Cardiology, Division of Electrophysiology, North Shore University Hospital,
Northwell Health, Manhasset, New York.
Introduction
First described in the 1990s, the Brugada syndrome initially
characterized unexplained sudden cardiac death in healthy
Southeast Asian men.1Mutations in the cardiac sodium chan-
nel were later identified in the SCN5A and SCN10A genes, ac-
counting for nearly 50% of the cases.2,3 Brugada syndrome
phenotype is associated with decrease in the sodium current
owing to reduction in sodium channels and/or reduction of
function of the sodium channels. Although the reduction in
the sodium current manifests with characteristic electrocar-
diographic abnormalities, patients with the Brugada syn-
drome are often healthy and unaware of their genetic
predisposition. As a result, the diagnosis of Brugada syn-
drome is often made after syncope or aborted sudden cardiac
arrest.4
Fever, alcohol, and medications causing sodium channel
blockade are well-described provocative triggers that may
incite arrhythmia in patients with Brugada syndrome.5
Here, we report a novel case of syncope due to Coronavirus
Disease 2019 (COVID-19)-induced fever in a patient with
previously unrecognized Brugada syndrome.
Case report
A 49-year-old Bangladeshi man without significant medical
history presented after an episode of syncope. A colleague
witnessed the patient suddenly lose consciousness while
sitting in his chair at work. The patient regained conscious-
ness after 1–2 minutes with no postictal symptoms. He re-
ported a day of subjective fevers, which he attributed to
hepatitis B vaccination received 48 hours prior to presenta-
tion. He had experienced a similar reaction after his first in-
jection a month prior. He denied similar episodes in the
past and also denied recent travel or sick contacts. Notably,
the patient’s younger brother had a similar episode of syn-
cope approximately a year ago; there was no family history
of sudden cardiac death.
Upon presentation, the patient was afebrile with otherwise
stable vital signs. An ST-elevation myocardial infarction was
called following acquisition of his first electrocardiogram
(ECG) (Figure 1) and the patient was taken for urgent coro-
nary angiogram, which showed normal coronary arteries.
Transthoracic echocardiogram was performed, which
showed preserved cardiac function with no anatomic abnor-
malities. No pericardial or pleural effusions were noted. He
was admitted for further evaluation. Overnight, the patient
spiked a fever of 102F with ECG changes, as shown in
Figure 2. Given his persistent fevers overnight, the patient
was placed on airborne isolation and tested for COVID-19
(UTM: Viral Transport; Copan, Murrieta, CA).
The patient’s fever improved with Tylenol and he re-
mained asymptomatic with no respiratory symptoms,
including cough and dyspnea. With defervescence, the pa-
tient’s ECG changes were noted, as shown in Figure 3. There
were no significant arrhythmic events, including premature
ventricular contractions and nonsustained ventricular tachy-
cardia observed on telemetry. The respiratory viral panel
and blood cultures were unremarkable. Approximately
24 hours after the viral swab was collected, the patient tested
positive for COVID-19. He remained in airborne isolation for
7 days owing to persistent fevers but had no respiratory
symptoms. The patient was discharged with a LifeVest
(Zoll Medical, Pittsburgh, PA) with plan for outpatient car-
diac magnetic resonance imaging and eventual implantation
of a subcutaneous defibrillator when cleared from home
KEY TEACHING POINTS
 Fever is the most common clinical presentation in
patients tested positive for COVID-19.
 Uncontrolled fever in patients with Brugada
syndrome portends higher risk for syncope and
sudden cardiac arrest.
 Health care providers encountering febrile patients
with suspicious electrocardiogram findings must
address all potential infectious etiologies and treat
the fever.
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quarantine. The medical staff in contact with the patient was
screened and high-risk staff members were sent for the
COVID-19 tests and quarantined.
Discussion
Patients with the Brugada syndrome, a combination of the
Brugada ECG pattern, clinical symptoms, and/or pertinent
family history commonly present with an episode of syncope
or aborted sudden cardiac arrest from ventricular arrhythmia.6
The 2 common Brugada ECG patterns are the type 1 Brugada
ECG pattern “coved” with the ST-segment elevation that
concaves down with inverted T waves in V1-V2 and the
type 2 Brugada ECG pattern with the “saddle-back”
ST-segment elevation and an upright or biphasic T waves in
V1-V2.
7 Of the 2 types, the type 1 Brugada ECG pattern has
a higher risk for ventricular arrhythmias.8 Patients with a
type 1 Brugada ECG pattern and pertinent clinical features
such as a personal history of syncope, ventricular arrhythmia,
or family history of sudden cardiac death meet the diagnosis
for Brugada syndrome. Those with a type 2 Brugada ECG
pattern and pertinent clinical features require a class I antiar-
rhythmic drug challenge to induce a type 1 Brugada ECG
pattern in order to meet the diagnosis of Brugada syndrome.9
Discerning the difference between Brugada syndrome and
the Brugada pattern with no relevant clinical features is
important for patient management. An implantable
cardioverter-defibrillator implantation is a class 1 indication
in patients with Brugada syndrome who survived a cardiac
arrest and/or who have a history of spontaneous sustained
ventricular tachycardia.9 On the other hand, asymptomatic
patients with the Brugada ECG pattern but no clinical signs
and family history suggestive of Brugada syndrome do not
benefit from a defibrillator.10
Figure 1 The patient’s initial 12-lead electrocardiogram in the emergency department.
Figure 2 The patient’s repeat 12-lead electrocardiogram with a fever of 102F.
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In patients without a clear indication for an implantable
cardioverter-defibrillator but presenting with high clinical sus-
picion for Brugada syndrome, other clues may help guide
treatment. Provocative triggers such as fever, alcohol, and
medications may unmask a type 1 Brugada ECG pattern.11
For instance, a patient with a type 2 Brugada ECG pattern at
rest presenting with a fever and a “coved” ST elevation resem-
bling a type 1 Brugada ECG pattern may be diagnosed with
Brugada syndrome without an antiarrhythmic drug challenge.
Fever is shown to precipitate arrhythmia in patients with
Brugada syndrome, and 1 study showed that more than half
of the study cohort experienced syncope or cardiac arrest in
the setting of a fever.12,13 The biophysical properties of the
cardiac sodium channel worsen at higher temperatures.14
Although the functional decline in mutated sodium channels
in patients with Brugada syndrome from a physiological tem-
perature to a higher temperature may be minimal, the loss of
function of the intact sodium channels may clinically trans-
late into a fever-induced arrhythmia.15 In addition, the
shortening of the intraepicardial dispersion of action potential
duration owing to elevated temperature may facilitate reen-
trant ventricular tachycardia.11
COVID-19 was first identified in Wuhan, China, in early
December 2019 as a case of pneumonia with unknown etiol-
ogy.12 In January 2020, the novel viral pathogen was identi-
fied, and with rapid spread was declared an international
pandemic in March 2020.12–14 The severe inflammatory
response to COVID-19 results in a febrile illness in the vast
majority of patients.15 As shown in our case, COVID-19-
induced fever led to symptomatic Brugada syndrome.
Conclusion
Symptomatic COVID-19 infection is typified by high fever, a
known precipitant of arrhythmia in patients with Brugada
syndrome. In addition to standard isolation procedures for
patients diagnosed with COVID-19, those with known or
suspected Brugada ECG patterns may warrant more aggres-
sive antipyretic therapy and serial screening ECGs. In addi-
tion, when managing a febrile patient with syncope, an
ECG must be a part of the evaluation. Defibrillator implanta-
tion should be strongly considered in individuals with a pro-
voked type 1 Brugada ECG pattern.
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